BAVARIAN NORDIC A/S (BV3.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:BV3 - DK0015998017 - Common Stock
24.53 EUR
-0.5 (-2%)
We assign a fundamental rating of 6 out of 10 to BV3. BV3 was compared to 83 industry peers in the Biotechnology industry. While BV3 has a great health rating, its profitability is only average at the moment. BV3 scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings could make BV3 a good candidate for value investing.
1. Profitability
1.1 Basic Checks
In the past year BV3 was profitable.
In the past year BV3 had a positive cash flow from operations.
In multiple years BV3 reported negative net income over the last 5 years.
BV3 had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
BV3's Return On Assets of 16.13% is amongst the best of the industry. BV3 outperforms 89.16% of its industry peers.
BV3 has a Return On Equity of 18.58%. This is amongst the best in the industry. BV3 outperforms 85.54% of its industry peers.
BV3 has a better Return On Invested Capital (13.14%) than 86.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.13% | ||
| ROE | 18.58% | ||
| ROIC | 13.14% |
ROA(3y)4.78%
ROA(5y)2.73%
ROE(3y)6.02%
ROE(5y)3.49%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BV3's Profit Margin of 35.50% is amongst the best of the industry. BV3 outperforms 87.95% of its industry peers.
BV3's Operating Margin of 36.21% is amongst the best of the industry. BV3 outperforms 90.36% of its industry peers.
BV3 has a Gross Margin (54.33%) which is in line with its industry peers.
In the last couple of years the Gross Margin of BV3 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 36.21% | ||
| PM (TTM) | 35.5% | ||
| GM | 54.33% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.91%
GM growth 5Y1.2%
2. Health
2.1 Basic Checks
BV3 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, BV3 has more shares outstanding
The number of shares outstanding for BV3 has been increased compared to 5 years ago.
The debt/assets ratio for BV3 has been reduced compared to a year ago.
2.2 Solvency
BV3 has an Altman-Z score of 6.89. This indicates that BV3 is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.89, BV3 belongs to the top of the industry, outperforming 81.93% of the companies in the same industry.
BV3 has a debt to FCF ratio of 0.10. This is a very positive value and a sign of high solvency as it would only need 0.10 years to pay back of all of its debts.
BV3's Debt to FCF ratio of 0.10 is amongst the best of the industry. BV3 outperforms 96.39% of its industry peers.
BV3 has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.01, BV3 belongs to the top of the industry, outperforming 84.34% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.1 | ||
| Altman-Z | 6.89 |
ROIC/WACC1.73
WACC7.6%
2.3 Liquidity
BV3 has a Current Ratio of 3.84. This indicates that BV3 is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 3.84, BV3 is doing good in the industry, outperforming 69.88% of the companies in the same industry.
A Quick Ratio of 2.43 indicates that BV3 has no problem at all paying its short term obligations.
BV3 has a Quick ratio of 2.43. This is comparable to the rest of the industry: BV3 outperforms 56.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.84 | ||
| Quick Ratio | 2.43 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 39.44% over the past year.
The Revenue has grown by 13.47% in the past year. This is quite good.
Measured over the past years, BV3 shows a very strong growth in Revenue. The Revenue has been growing by 53.88% on average per year.
EPS 1Y (TTM)39.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%414.42%
Revenue 1Y (TTM)13.47%
Revenue growth 3Y44.42%
Revenue growth 5Y53.88%
Sales Q2Q%32.58%
3.2 Future
The Earnings Per Share is expected to grow by 4.71% on average over the next years.
The Revenue is expected to grow by 2.12% on average over the next years.
EPS Next Y54.87%
EPS Next 2Y-4.62%
EPS Next 3Y1.7%
EPS Next 5Y4.71%
Revenue Next Year11.61%
Revenue Next 2Y1.22%
Revenue Next 3Y0.68%
Revenue Next 5Y2.12%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 10.81, the valuation of BV3 can be described as very reasonable.
90.36% of the companies in the same industry are more expensive than BV3, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.43. BV3 is valued rather cheaply when compared to this.
With a Price/Forward Earnings ratio of 19.24, BV3 is valued on the expensive side.
Based on the Price/Forward Earnings ratio, BV3 is valued cheaper than 85.54% of the companies in the same industry.
BV3's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.66.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.81 | ||
| Fwd PE | 19.24 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BV3 is valued cheaply inside the industry as 92.77% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, BV3 is valued cheaper than 90.36% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.31 | ||
| EV/EBITDA | 3.37 |
4.3 Compensation for Growth
BV3's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BV3 has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.2
PEG (5Y)N/A
EPS Next 2Y-4.62%
EPS Next 3Y1.7%
5. Dividend
5.1 Amount
No dividends for BV3!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:BV3 (12/16/2025, 7:00:00 PM)
24.53
-0.5 (-2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners30.53%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap1.94B
Revenue(TTM)6.89B
Net Income(TTM)2.44B
Analysts80
Price Target34.12 (39.09%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-29.73%
PT rev (3m)-29.73%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-32.84%
EPS NY rev (3m)-32.84%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.6%
Revenue NY rev (3m)-0.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.81 | ||
| Fwd PE | 19.24 | ||
| P/S | 2.11 | ||
| P/FCF | 11.31 | ||
| P/OCF | 4.64 | ||
| P/B | 1.1 | ||
| P/tB | 2.03 | ||
| EV/EBITDA | 3.37 |
EPS(TTM)2.27
EY9.25%
EPS(NY)1.28
Fwd EY5.2%
FCF(TTM)2.17
FCFY8.84%
OCF(TTM)5.29
OCFY21.57%
SpS11.63
BVpS22.23
TBVpS12.06
PEG (NY)0.2
PEG (5Y)N/A
Graham Number33.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.13% | ||
| ROE | 18.58% | ||
| ROCE | 18.66% | ||
| ROIC | 13.14% | ||
| ROICexc | 16.9% | ||
| ROICexgc | 40.21% | ||
| OM | 36.21% | ||
| PM (TTM) | 35.5% | ||
| GM | 54.33% | ||
| FCFM | 18.64% |
ROA(3y)4.78%
ROA(5y)2.73%
ROE(3y)6.02%
ROE(5y)3.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.91%
GM growth 5Y1.2%
F-Score8
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.1 | ||
| Debt/EBITDA | 0.03 | ||
| Cap/Depr | 262.4% | ||
| Cap/Sales | 26.84% | ||
| Interest Coverage | 81.71 | ||
| Cash Conversion | 97.94% | ||
| Profit Quality | 52.5% | ||
| Current Ratio | 3.84 | ||
| Quick Ratio | 2.43 | ||
| Altman-Z | 6.89 |
F-Score8
WACC7.6%
ROIC/WACC1.73
Cap/Depr(3y)229.46%
Cap/Depr(5y)231.44%
Cap/Sales(3y)29.07%
Cap/Sales(5y)36.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%414.42%
EPS Next Y54.87%
EPS Next 2Y-4.62%
EPS Next 3Y1.7%
EPS Next 5Y4.71%
Revenue 1Y (TTM)13.47%
Revenue growth 3Y44.42%
Revenue growth 5Y53.88%
Sales Q2Q%32.58%
Revenue Next Year11.61%
Revenue Next 2Y1.22%
Revenue Next 3Y0.68%
Revenue Next 5Y2.12%
EBIT growth 1Y125.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year133.26%
EBIT Next 3Y26.17%
EBIT Next 5Y15.19%
FCF growth 1Y262.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y316.96%
OCF growth 3YN/A
OCF growth 5YN/A
BAVARIAN NORDIC A/S / BV3.DE FAQ
Can you provide the ChartMill fundamental rating for BAVARIAN NORDIC A/S?
ChartMill assigns a fundamental rating of 6 / 10 to BV3.DE.
Can you provide the valuation status for BAVARIAN NORDIC A/S?
ChartMill assigns a valuation rating of 7 / 10 to BAVARIAN NORDIC A/S (BV3.DE). This can be considered as Undervalued.
Can you provide the profitability details for BAVARIAN NORDIC A/S?
BAVARIAN NORDIC A/S (BV3.DE) has a profitability rating of 6 / 10.
Can you provide the financial health for BV3 stock?
The financial health rating of BAVARIAN NORDIC A/S (BV3.DE) is 8 / 10.